ImmuPharma PLC (IMM) - Total Liabilities

Latest as of June 2025: GBX1.24 Million GBX ≈ $151.37 USD

Based on the latest financial reports, ImmuPharma PLC (IMM) has total liabilities worth GBX1.24 Million GBX (≈ $151.37 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ImmuPharma PLC - Total Liabilities Trend (2004–2024)

This chart illustrates how ImmuPharma PLC's total liabilities have evolved over time, based on quarterly financial data. See how liquid is ImmuPharma PLC's working capital to evaluate short-term liquidity relative to the company's equity base.

ImmuPharma PLC Competitors by Total Liabilities

The table below lists competitors of ImmuPharma PLC ranked by their total liabilities.

Company	Country	Total Liabilities
Virpax Pharmaceuticals Inc NASDAQ:VRPX	USA	$2.47 Million
Kendrick Resources PLC LSE:KEN	UK	GBX1.09 Million
Baltic Bridge S.A. WAR:WIS	Poland	zł6.36 Million
Greiffenberger AG F:GRF	Germany	€31.02 Million
Water Ways Technologies Inc V:WWT	Canada	CA$5.93 Million
VATIC VENTURES CORP. F:V8V	Germany	€1.69 Million
Alchimie Sa PA:ALCHI	France	€15.31 Million
EGR EXPL LTD F:Z0R	Germany	€231.51K

Liability Composition Analysis (2004–2024)

This chart breaks down ImmuPharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ImmuPharma PLC (IMM) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.21	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.69	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ImmuPharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ImmuPharma PLC (2004–2024)

The table below shows the annual total liabilities of ImmuPharma PLC from 2004 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX1.52 Million ≈ $184.92	-8.72%
2023-12-31	GBX1.67 Million ≈ $202.60	+14.73%
2022-12-31	GBX1.45 Million ≈ $176.58	-8.39%
2021-12-31	GBX1.58 Million ≈ $192.76	+25.65%
2020-12-31	GBX1.26 Million ≈ $153.41	+137.07%
2019-12-31	GBX531.87K ≈ $64.71	-48.60%
2018-12-31	GBX1.03 Million ≈ $125.90	-28.28%
2017-12-31	GBX1.44 Million ≈ $175.54	+23.97%
2016-12-31	GBX1.16 Million ≈ $141.60	-23.57%
2015-12-31	GBX1.52 Million ≈ $185.26	+11.39%
2014-12-31	GBX1.37 Million ≈ $166.32	-24.12%
2013-12-31	GBX1.80 Million ≈ $219.19	-13.87%
2012-12-31	GBX2.09 Million ≈ $254.48	+17.97%
2011-12-31	GBX1.77 Million ≈ $215.72	+12.07%
2010-12-31	GBX1.58 Million ≈ $192.48	-75.88%
2009-12-31	GBX6.56 Million ≈ $798.16	+203.42%
2008-12-31	GBX2.16 Million ≈ $263.05	+105.90%
2007-12-31	GBX1.05 Million ≈ $127.75	-27.03%
2006-12-31	GBX1.44 Million ≈ $175.08	+28.14%
2006-03-31	GBX1.12 Million ≈ $136.64	+7921.43%
2005-03-31	GBX14.00K ≈ $1.70	+600.00%
2004-03-31	GBX2.00K ≈ $0.24	--

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$269.44K

GBX2.21 Billion GBX

Market Cap Rank

#31037 Global

#989 in UK

Share Price

GBX4.41

Change (1 day)

+0.00%

52-Week Range

GBX1.50 - GBX17.60

All Time High

GBX190.00